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Background: The natural history of HIV infection has changed dramatically after the
introduction  of highly active antiretroviral therapy. Currently, opportunistic illnesses still
represent a major cause of death and hospitalization in this population. In this study,
we  review the trends in opportunistic illnesses incidence rates and compare the results
observed  in high-income settings with that for low/middle-income settings, with special
attention  given to studies from Brazil.
Methods: We  systematically searched Pubmed, Web  of Science, Lilacs and Google scholar
for  publications on HIV associated opportunistic illness. Studies reporting rates based on
person-time  for all opportunistic illnesses and/or the three opportunistic infections of
interest, namely, Pneumocystis carinii pneumonia, cerebral toxoplasmosis, and Mycobacterium
avium  complex were included.
Results:  Signiﬁcant reductions in the incidence rates were demonstrated for opportunistic
illnesses  overall and also for the speciﬁc opportunistic infections included in the present
study,  both in high and low/middle-income settings. Out of the 37 studies included in the
present  review, almost 70% were from high-income settings. All the studies conducted in
low/middle-income settings were single center studies and four were from Brazil. We found
no study from Brazil reporting annual incidence rates of opportunistic illnesses.
Conclusions: Opportunistic illnesses remain an important public health problem. To better
guide health policies in low/middle-income settings, multicenter cohort studies should befromencouraged. Studies tunistic illnesses in our p
services  organization.
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ntroduction
he natural history of human immunodeﬁciency virus (HIV)
nfection  and acquired immunodeﬁciency syndrome (AIDS)
as  changed dramatically since the onset of the epidemic
n  the 1980s. The landmark of this process was  the intro-
uction  of highly active antiretroviral therapy (ART) in 1996.
espite  the progress made in the treatment and control of
IV  infection, HIV/AIDS persists as one of the main causes
f  death in the world, affecting individuals from both high-
ncome  and low-income settings.1 In addition, although an
ncrease  in non-AIDS associated morbidity and mortality has
een observed, opportunistic infections remain a major cause
f  hospitalization and death in people living with HIV/AIDS in
igh and low-income settings.2–4
Currently, in the post-ART period, opportunistic illnesses
re  mainly related with late diagnosis and/or presentation to
are, non-adherence to ART and HIV resistance to antiretrovi-
al  drugs.2,5 Late diagnosis and/or presentation to care is one
f  the most challenging aspects of the HIV epidemic. In Brazil,
4%  of the patients still present with an opportunistic illness at
he moment of ART initiation.6 Furthermore, non-adherence
o  ART results in virologic failure and disease progression.
actors associated with non-adherence, such as low educa-
ional  level, young age, unemployment, alcoholism and use
f  illicit drugs represent an important socioeconomic prob-
em,  in particular for low/middle-income settings.7,8 Finally,
ultidrug resistance to antiretroviral drugs is a consequence
f  HIV exposure to ART, particularly in settings where non-
dherence  prevails.9
In this study, we review the trends in opportunistic ill-
esses  incidence rates and compare the results observed in
igh-income  settings (HIS) with that for low/middle-income
ettings (LMIS), with special attention given to studies from
razil.  We  evaluate the impact ART has had in three speciﬁc
pportunistic infections of particular importance to Brazil and
ontrast  the patterns in the countries evaluated.
earch  strategy  and  selection  criteria
ublications related to AIDS-associated opportunistic ill-
esses  incidence were  identiﬁed by systematically searching
n  Pubmed, Web  of Science, Lilacs and Google scholar. Pub-
ications  were  restricted to the following languages: English,
ortuguese, and Spanish. The databases were searched for
tudies  published until January 2013 using the following
earch terms and Boolean operators, for matches under any
eld:  (incidence) AND (HIV OR human immunodeﬁciency
irus) AND (AIDS-deﬁning illness OR opportunistic infection
R  opportunistic disease OR AIDS-related opportunistic infec-
ion  OR AIDS-related opportunistic illness). For the Lilacs
atabase, search terms were  translated into Portuguese lan-
uage  and separate searches with each term were conducted.
itles  and available abstracts were scanned for relevance
dentifying papers requiring further consideration. Bibliogra-
hies  of relevant articles were also checked. Inclusion criteria
onsisted  in (1) presence of a person-time denominator and (2)
esults for all opportunistic illnesses and/or the three oppor-4;1 8(2):196–210  197
tunistic infections of interest, namely: Pneumocystis carinii
pneumonia (PCP), cerebral toxoplasmosis (NTX) and Mycobac-
terium  avium complex (MAC). Exclusion criteria included: (1)
results  given only for hospitalization and/or severe diseases,
(2)  results given relative terms only (that is, as incidence rate
ratios,  odds ratios or relative risks), (3) results given only
for  Immune Reconstitution Inﬂammatory Syndrome, and (4)
results that aggregate death and opportunistic infections in
one outcome. The results, inclusion and exclusion criteria are
shown in Fig. 1.
Results
Thirty seven publications met  the study’s eligibility criteria, 25
from  HIS and 12 studies from LMIS (Fig. 1).2,10–45 Out of the 12
studies  from LMIS, four were  from Latin America, speciﬁcally
from  Brazil. Results from these studies are summarized in the
next  sections with incidence rates in 100 person-years (100 PY)
format.
Opportunistic  illnesses
Table 1 summarizes the ﬁndings for the incidence rate of
opportunistic illnesses from 1984 to 2010 in HIS and LMIS.
Depending on the study, incidence rates ranged from 2.3 to
12.3  times lower in the post-ART period compared to the pre-
ART  period.
In  HIS, a multicenter study conducted in the United States
using  data from the HIV Outpatient Study (HOPS) cohort with
no  CD4+ cell count restriction of the study population reported
that  the incidence rate of opportunistic illnesses decreased
from  9.24/100 PY in pre-ART period to 1.66/100 PY in post-ART
period.2 A more  striking result was  reported for the Eurosida
cohort, an European multicenter cohort that included only
patients  with CD4+ cell counts less than 500 cells/mm3 where
the  incidence rate of opportunistic illnesses decreased from
30.7/100  PY in the pre-ART period to 2.5/100 PY in the post-ART
period.10 Similarly, a study from Spain that included patients
with  CD4+ cell counts less than 500 cells/mm3 reported signiﬁ-
cant  decreases in the incidence rate of opportunistic illnesses,
which  went from 43.2/100 PY to 14.6/100 PY, in the pre and
post-ART  periods, respectively.11 Other studies conducted in
HIS can be found in Table 1, including results from England,
Canada, Switzerland and Germany.
In LMIS, in a study from Thailand with no CD4+ cell count
restriction of the study population, the incidence rate of oppor-
tunistic  illnesses decreased from 19.1/100 PY in the absence
of  ART to 8.2/100 PY after ART use.12 A study conducted in
São  Paulo in the period of 1986 through 1997, also with no
CD4+ cell count restriction of the study population, reported
an  incidence rate of opportunistic illnesses of 12.24/100 PY
in  a supposedly pre-ART period.13 Another study conducted
with the same population during the period from 1987 to 2002
estimated  a lower incidence rate of opportunistic illnesses of
144.6/100  PY. A study from Rio de Janeiro, that included only
patients  with CD4+ counts less than 100 cells/mm3 in the
period  of 1997 to 1999, found an incidence rate of opportunistic
illnesses of 29/100 PY a supposedly post-ART period.15 Other
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Table 1 – Incidence rates for opportunistic illnesses among HIV-infected individuals from high and low/middle-income settings.
First author, year, journal Setting and cohort
(when  applicable)
Time period evaluated Incidence rate estimate Notes
High-income settings
Cain,  2009, American
Journal  of Epidemiology
Baltimore,
Pittsburgh,  Chicago
and  Los Angeles, US,
MACS  cohort
1984a to April 2007 Entire period: 5.23/100 PY;
Before  1996: 7.53/100 PY;
After1996:  2.19/100 PY
Patient  inclusion criteria: no CD4 criteria,
MSM only; Disease deﬁnition: CDC 1993,
considers only the ﬁrst ADI after cohort
enrollment
Mocroft, 1999, Journal of
Acquired  Immune
Deﬁciency Syndromes
London,  UK, Royal
Free  Center for HIV
Medicine
1987a to 1998a Before 1992: 27.4/100 PY;
1992–1993:  16.8/100 PY;
1994:  17.9/100 PY; 1995:
19.3/100  PY; 1996: 16.7/100
PY;  1997: 6.9/100 PY
Patient  inclusion criteria: no CD4 criteria;
Disease deﬁnition: CDC 1993, considers
only  the ﬁrst ADI after cohort enrollment
San-Andres, 2003, Clinical
Infectious Diseases
Madrid,  Spain,
University Hospital
January 1989–1997a 1989–1991: 36.4/100 PY;
1992:  43.2/100 PY; 1993:
39.0/100  PY; 1994: 32.4/100
PY;  1995: 32.0/100 PY; 1996:
30.9/100  PY; 1997: 14.6/100
PY
Patient  inclusion criteria: CD4 less than
500 cells/mm3 or previous AIDS diagnosis;
Disease deﬁnition: not clearly stated,
likely  considers all ADIb episodes after
cohort enrollment
Charurat, 2004, Journal of
Women’s  Health
4  states in US and
Puerto  Rico, WITS
Cohort
December  1989 to
June  2002
Before Feb/1994: 4.52/100
PY;  Mar/1994 to Jul/1996:
5.09/100  PY; After Aug/1996:
1.22/100  PY
Patient  inclusion criteria: no CD4 criteria,
only women without previous diagnosis
of AIDS; Disease deﬁnition: CDC 1993;
considers only the ﬁrst ADI after cohort
enrollment
Kaplan, 2000, Clinical
Infectious  Diseases
10  US cities,
Adults/Adolescents
Spectrum of HIV
Disease  (ASD) Study
1992a to September
1999
1996–1998: 16/100 PYc Patient inclusion criteria: no CD4 criteria;
Disease deﬁnition: not clearly stated,
likely  considers all ADId episodes after
cohort enrollment
Forrest, 1998, Clinical
Infectious  Diseases
British  Columbia,
Canada, British
Columbia Center for
Excellence  in
HIV/AIDS
January  1994 to
December  1996
1994: 8/100 PY; 1996: 2.2/100
PY
Patient  inclusion criteria: no CD4 criteria,
included only patients in use of
antiretroviral  drugs; Disease deﬁnition:
CDC  1993; considers only the ﬁrst ADI
after cohort enrollment
Mocroft, 2000, Lancet 51 centers in Europe,
Eurosida  cohort
May 1994 to spring
1999a
1994: 30.7/100 PY; 1998:
2.5/100  PYc
Patient inclusion criteria: CD4 < 500
cells/mm3; Disease deﬁnition: CDC 1993,
considers the ﬁrst ADI after cohort
enrollment
Buchacz, 2010, AIDS 12 centers in US,
HOPS  cohort
January 1994 to
December  2007
1994–1997: 9.24/100 PY;
1998–2002:  2.96/100 PY;
2003–2007:  1.66/100 PY
Patient  inclusion criteria: no CD4 criteria;
Disease deﬁnition: CDC 1993e; considers
only the ﬁrst ADI after cohort enrollment
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Table 1 (Continued )
First author, year, journal Setting  and cohort
(when  applicable)
Time period evaluated Incidence rate estimate Notes
Ledergerber, 1999, Journal
of  the American
Medical Association
7  centers in
Switzerland, Swiss
HIV  Cohort Study
September 1995 to
March  1999
Before to ART use: 15.1/100
PY;  after ART use: 3.57/100
PY
Patient  inclusion criteria: no CD4 criteria,
included patients who started ART
between  September 1995 and December
1997.  Disease deﬁnition: CDC 1993,
considers  only the ﬁrst ADI after cohort
enrollment
Wohl, 2003, Aids Patient
Care  and STDs
10  US cities, ASD
cohort
1996a to 2000a US born: 21.0/100 PY;
Mexican  born: 16.6/100 PY;
Central  American born:
13.9/100  PY
Patient  inclusion criteria: no CD4 criteria;
included US born Latinos, Mexican born
Latinos and Central American Latinos.
Disease  deﬁnition: not clear stated,
apparently included all ADI presented in
the study period.
Plettenberg, 2011,
Infection
Germany,  KompNet
cohort
1996a to 2010f Group 1: 1.38/100 PY; Group
2:  0.78/100 PY
Patient  inclusion criteria: patients who
started antiretroviral treatment.g Disease
deﬁnition: included the ﬁrst episode of an
ADI after antiretroviral therapy.
Low/middle-income settings
Fonseca,  1999,
International Journal of
Epidemiology
São  Paulo, Brazil,
University of São
Paulo
1986a to June 1997 12.24/100 PY (converted
from  10.2/1000 PM)
Patient  inclusion criteria: asymptomatic
patients; Disease deﬁnition: CDC 1987,
modiﬁed to include pulmonary
tuberculosis  as an AIDS
deﬁning-condition, considers only the
ﬁrst ADI after cohort enrollment
Casseb, 2003, AIDS
Patient  care and STDs
São  Paulo, Brazil,
University of São
Paulo
October  1987 to
February  2002
4.6/100 PY (converted from
3.84/1000PM)
Patient  inclusion criteria: asymptomatic
patients; Disease deﬁnition: CDC 1987,
considers only the ﬁrst ADI after cohort
enrollment
Badri, 2005, The Southern
African  Journal of HIV
Medicine
Cape  Town, South
Africa,  Cape Town
AIDS  Cohort (CTAC)
1992a to December
2000
21.34/100 PY Patient inclusion criteria: no CD4 criteria;
Disease deﬁnition: WHO 1990, considers
all  ADI episodes after cohort enrollment
Losina, 2007, Antiviral
Therapy
Abidjan,  Ivory Coast,
Cotrimo  CI ANRS 059
and Cotrame
ANRS1203
1996a to July 2003 Cotrimoxazole alone: CD4
less  than 50 cells/mm3:
20.17/100 PY; CD4 above 200
cells/mm3: 3.54/100 PY;
Cotrimoxazole plus ART
(0–6  months): CD4 less 50
cells/mm3: 20.22/100 PY,
CD4 > 200 cells/mm3:
2.79/100  PY; Cotrimoxazole
plus  ART (>6 months):
CD4  < 50 cells/mm3:
6.84/100  PY, CD4 > 200
cells/mm3: 1.68/100 PY
Patient inclusion: Patients participating in
Cotrimo ANRS and Cotrame ANRS
studies.  Disease deﬁnition: considers only
the ﬁrst ADIh presented in each periodi of
study. Results were stratiﬁed by use of
cotrimoxazole prophylaxis, ART and CD4
counts.
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Table 1 (Continued )
First author, year, journal Setting  and cohort
(when  applicable)
Time period evaluated Incidence rate estimate Notes
Gadelha, 2002, Rev Inst
Med  Trop Sao Paulo
Rio  de Janeiro, Brazil,
IPEC cohort
September  1997 to
December  1999
29/100 PYj Patient inclusion criteria: at least one
CD4 < 100 cells/mm3, included patients
who started ART between September
1995  and December 1997. Disease
deﬁnition:  CDC 1993, considers the ﬁrst
ADI after cohort enrollment
De Beaudrap, 2010, BMC
Infectious  Diseases
Senegal,  Initative
Sénégalaise d’Acèss
aux  médicaments
Antiretrovirauxk
August 1998 to April
2008
First year after ART
initiation:  20.5/100 PY. Over
the  fourth year after ART
initiation:  4.3/100 PY
Patient  inclusion criteria: no CD4 criteria.
Disease deﬁnition: CDC 1993, considered
the  ﬁrst episode of each ADI presented
after  ART initiation. Results were
stratiﬁed  by timing of ART use
Podlasin, 2006, Infection 10 centers in Poland 2000a to 2002a Total: 2.4/100 PY; 2000:
6.8/100  PY; 2001: 6.5/100 PY;
2002:  4.8/100 PY
Patient  inclusion criteria: none; Disease
deﬁnition: CDC 1993, not clearly stated,
likely considers all ADI after cohort
enrollment
Rojanawiwat, 2011,
International  Health
Lampang,  Thailand,
Governmental
Referral  Hospitall
July 2000 to October
2004
Prior to ART: 19.1/100 PY;
After  ART use: 8.2/100 PY
Patient  inclusion criteria: no CD4 criteria;
Disease deﬁnition: included the ﬁrst
episode of all ADIm presented by the
patient
ADI: AIDS deﬁning illness; CDC: Centers for Disease Control; CMV: cytomegalovirus; MAC: Mycobacterium avium complex; MSM: men who have sex with men; PCP: Pneumocystis carinii pneumonia.
a Month not speciﬁed.
b Does not specify the criteria used for ADI, the results include: Esophageal candidiasis, PCP, tuberculosis, wasting syndrome, cerebral toxoplasmosis, Kaposi’s sarcoma, AIDS dementia complex,
progressive multifocal leukoencephalopathy, primary brain lymphoma, CMV disease, MAC, non-Hodgkin lymphoma, cryptosporidiosis, recurrent pneumonia, cryptococcosis, chronic herpes simplex,
invasive cervical cancer.
c Results for other years shown in ﬁgure format only, thus not reported here.
d Diseases included: PCP, disseminated MAC, cerebral toxoplasmosis, Kaposi’s sarcoma, CMV retinitis, esophageal candidiasis, cryptococcosis.
e Excluded diseases: recurrent pneumonia, Salmonella septicemia and wasting syndrome.
f Time inferred from information contained in the text.
g Patients were separated into two groups: Group 1: patients who started ART with CD4 between 250 and 349 cells/mm3; Group 2: patients who started ART with CD4 between 350 and 450 cells/mm3.
h Diseases included: severe bacterial infections (pneumonia, enteritis, bacteremia, invasive urogenital infection), malaria, cerebral toxoplasmosis, isosporosis, PCP, extrapulmonar cryptococosis,
esophageal candidiasis, tuberculosis, MAC, other WHO clinical stage 3 and 4.
i In the ﬁrst period (until December 1998), patients received cotrimoxazole prophylaxis. In the second period (after December 1998) patients received ART plus cotrimoxazole prophylaxis (the later
period was separated in the ﬁrst 6 months after ART initiation and after 6 months of ART initiation).
j Data from de prospective period.
k Antiretroviral drugs available for free since December 2003.
l In 2002 the government introduced the co-formulation stavudine, lamivudine and nevirapine (on a pilot basis). The use of this medication gradually increased especially after 2004.
m Does not specify the criteria used for ADI, the results include: tuberculosis, PCP, cryptococcal meningitis, penicilliosis, esophageal candidiasis, herpes zoster, cerebral toxoplasmosis, CMV retinitis.
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Pubmed:
297 results
48 abstracts
examined
48 abstracts
examined
13 abstracts
examined
92 abstracts
examined
Inclusion criteria: 1) Person-time denominator;
2) Results for all opportunistic illnesses and/or
PCP and/or NTX and/or MAC
Exclusion criteria (09 studies excluded): 1) Results for hospitalization
and/or severe disease only (2); 2) Results given relative terms only
(incidence rate ratios, odds ratios or relative risks) (3); 3) Results given
only for immune reconstitution inflammatory syndrome (2); 3) Results
that aggregate death and opportunistic infections in one outcome (2); 
12 studies from 
low/middle-income settings: 
Asia (2), Latin America (4),
Africa (5), Europe (1) 
25 studies from
high-income settings
37 studies analyzed
5 studies identified from
bibliography
41 potentially appropriate
studies
Web of science:
226 results
Lilacs:
101 results
Google scholar:
1530 results
1963 titles excluded due
to non-relevance
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tudies conducted in LMIS can be found in Table 1 and include
esults  from South Africa, Ivory Coast, Senegal and Poland.
neumocystis  carinii  pneumonia
able 2 summarizes the ﬁndings for PCP incidence rates from
982  to 2008 in HIS and LMIS. Depending on the study, inci-
ence  rates ranged from 2.0 to 15.6 times lower in the post-ART
eriod  compared to the pre-ART period.
In HIS, a study conducted in one center in England includ-
ng  all HIV-infected individuals showed that the incidence
ate  of PCP decreased from 9.1/100 PY in the pre-ART period
before  1992) to 1.9/100 PY in the post-ART period (in 1997).16
n even more  dramatic result was  reported in a study from
an  Francisco, United States, that used local surveillance data
f  the HIV-infected population and showed that the inci-
ence  rate of PCP dropped from 9.5/100 PY in pre-ART period
1993–1995)  to 0.85/100 PY in post-ART period (2001–2008).17
ther studies conducted in HIS can be found in Table 2, includ-
ng  results from France, Spain, Switzerland and Germany.
In  LMIS, a study from Taiwan that included all HIV-infected
ndividuals estimated that the incidence rate of PCP decreased
rom  70.5/100 PY in the pre-ART period (1995) to 9.2/100 PY in
he post-ART period (1999).18 In addition, a study from Thai-
and  that, again, included all HIV-infected patients reported
n  incidence rate of PCP decreasing from 4.7/100 PY in the
bsence  of ART to 0.3/100 PY after ART use.12 Other studies
onducted in LMIS can be found in Table 2 and include results
rom  South Africa and Poland. Unfortunately, we found no
tudy  from Brazil.
erebral  toxoplasmosis
able 3 summarizes the ﬁndings for NXT incidence rate from
985  to 2010 in HIS and LMIS. Depending on the study, inci-
ence  rates varied from 1.2 to 8.0 times lower in the post-ART
eriod  compared to the pre-ART period.In HIS, a multicenter cohort (Multicenter AIDS Cohort Study
 MACS) of HIV-infected men  who have sex with men  from
he  United States reported that the incidence rate of NTX
ecreased from 0.54/100 PY in pre-ART period (1990–1992) topers selection ﬂowchart.
0.22/100  PY in post-ART period (1996–1998).19 Data of the Swiss
cohort  (multicenter cohort) conﬁrmed this trend showing that
the  incidence rate of NTX among HIV-infected individuals
who started antiretroviral therapy between 1995 and 1997
decreased  from 1.45/100 PY before ART use to 0.18/100 PY after
ART  use.20 Also in HIS, in a multicenter study from United
Kingdom conducted among HIV-infected individuals reported
that  the incidence rate of NTX decreased from 0.32/100 PY in
the pre-ART period (1996–1997) to 0.04/100 PY in the post-ART
period  (1996–2007).21 Other studies conducted in HIS can be
found  in Table 3, including results from England, France, Spain,
Switzerland  and Germany.
In  LMIS, a study from Thailand that included all HIV-
infected patients estimated a reduction in the incidence rate of
NTX  from 1.2/100 PY in the absence of ART to 1.0/100 PY after
ART  use.12 Data from LMIS also include a study from South
Africa,  with no CD4+ cell count restriction of the study pop-
ulation,  with an incidence rate of NTX of 0.15/100 PY in the
period  of 1992–2000.22 Again, we unfortunately did not ﬁnd
any  study from Brazil.
Mycobacterium  avium  complex  disease
Table 4 summarizes the ﬁndings for MAC  incidence rate from
1985  to 2008 in HIS and LMIS. Depending on the study, inci-
dence  rates ranged from 2.4 to 25.8 times lower in the post-ART
period  compared to the pre-ART period.
In HIS, a surveillance study from San Francisco (United
States), with no CD4+ cell count restriction of the study
population, reported an incidence rate of MAC  decreasing
from 8.52/100 PY in pre-ART period (1993–1995) to 0.32/100
PY  in post-ART period (2001–2008).17 One study from Spain,
that  included only patients with CD4+ counts less than 500
cells/mm3, reported that the incidence rate of MAC  decreased
from  2.9/100 PY in pre-ART period (1992) to 0.6/100 PY in
post-ART  period (1997).11 In addition, data from the Swiss
+ 3Cohort for patients with CD4 counts less than 50 cells/mm ,
showed  an incidence rate of MAC  decreasing from 8.8/100 PY
in  pre-ART period (1990–1996) to 1.4/100 PY in post-ART period
(1997–1999).23 Other studies conducted in HIS can be found in
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Table 2 – Incidence rate for Pneumocystis carinii pneumonia among HIV-infected individuals from high and low/middle-income settings.
First author, year, journal Setting and cohort (when applicable) Time period evaluated Incidence rate estimate Notes
High-income settings
Mocroft,  1998, Archives of
Internal  Medicine
London,  England,
Chelsea  and
Westminster
Hospital and The
Royal  Free Hospital
1982a to July 1995 6.22/100 PY Patient inclusion criteria: no CD4 criteria;
Disease deﬁnition: considers only ﬁrst episode
after cohort enrollment
Bacellar, 1994, Journal of
Infectious  Diseases
Baltimore,
Pittsburgh,  Chicago
and  Los Angeles, US,
MACS  cohort
1985a to 1993a No antiretroviral nor PCP
prophylaxis:  3.1/100 PY; Only
antiretroviral:  1.8/100 PY;
Antiretroviral  and PCP
prophylaxis:  2.4/100 PY
Patient inclusion criteria: CD4 <  100 cells/mm3,
MSM only; Disease deﬁnition: considers only the
ﬁrst episode after cohort enrollment. Results
stratiﬁed by use of antiretroviralb and/or PCP
prophylaxis
Yazdanpanah, 2001,
International  Journal of
Epidemiology
France,  Tourcoing
and  Aquitaine
cohorts
January 1987 to
December  1995
>500  cells/mm3: 0.4/100 PY;
301–500 cells/mm3: 0.5/100 PY;
201–300 cells/mm3: 1.6/100 PY;
101–200 cells/mm3: 3.1/100 PY;
51–100 cells/mm3: 6.7/100 PY;
>50 cells/mm3: 11.4/100 PY;
Patient  exclusion criteria: patients in use of
antiretroviral therapy other than zidovudine
monotheray and prophylaxis; patients with less
than 3 CD4 counts; patients with prior PCP
diagnosis or PCP diagnosis in the ﬁrst cohort
visit and those in use of PCP prophylaxis.
Disease  deﬁnition: only the ﬁrst case after cohort
enrollment. Results stratiﬁed by CD4 counts
Mocroft, 1999, Journal of
Acquired  Immune
Deﬁciency Syndromes
London,  England,
Royal  Free Center for
HIV  Medicine
1987a to 1998a Before 1992: 9.1/100 PY;
1992–1993:  5.3/100 PY; 1994:
3.5/100  PY; 1995: 6.4/100 PY;
1996:  4.0/100 PY; 1997: 1.9/100
PY
Patient  inclusion criteria: no CD4 criteria;
Disease deﬁnition: only ﬁrst ADI was considered
after cohort enrollment
Moore, 1996, Annals of
Internal  Medicine
Baltimore,  US, Johns
Hopkins  Clinical
Cohort
July  1989 to April
1995
8.9/100 PY Patient inclusion criteria: CD4 <  300 cells/mm3;
Disease deﬁnition: only ﬁrst episode considered
after cohort enrollment
San-Andres, 2003, Clinical
Infectious Diseases
Madrid,  Spain,
University Hospital
January  1989 to
1997a
1989–1991: 5.5/100 PY; 1992:
5.4/100  PY; 1993: 3.5/100 PY;
1994:  3.4/100 PY; 1995: 3.0/100
PY;  1996: 3.3/100 PY; 1997:
0.6/100  PY
Patient inclusion criteria: CD4 <  500 cells/mm3 or
previous diagnosis of an ADI; Disease deﬁnition:
not clearly stated, likely considers all episodes
after cohort enrollment
Charurat, 2004, Journal of
Women’s  Health
4  states in US and
Puerto  Rico, WITS
Cohort
December 1989 to
June  2002
Before February 1994: 0.44/100
PY  March 1994 to July 1996:
0.86/100  PY After August 1996:
0.42/100  PY
Patient inclusion criteria: no CD4 criteria,
women only, without previous diagnosis of AIDS;
Disease deﬁnition: only ﬁrst episode considered
after cohort enrollment
Moorman, 1998, Journal
of  Acquired Immune
Deﬁciency  Syndromes
8  US cities, HOPS
cohort
January 1992 to June
1996
4.6/100  PY Patient inclusion criteria: patients in use of PCP
prophylaxis for at least 3 monthsc; Disease
deﬁnition:  all episodes considered after cohort
enrollment
Brodt, 1997, AIDS Frankfurt, Germany,
Frankfurt  AIDS
Cohort
January 1992 to
March  1997
1992: 17.8/100 PY; 1993: 18.2/100
PY; 1994: 16.3/100 PY; 1995:
9.9/100  PY; 1996: 6.4/100 PY
Patient inclusion criteria: CD4 <  200 cells/mm3,
MSM only; Disease deﬁnition: not clearly stated,
likely considers all episodes after cohort
enrollment
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Table 2 (Continued )
First author, year, journal Setting and cohort (when applicable) Time period evaluated Incidence rate estimate Notes
Kaplan, 2000, Clinical
Infectious  Diseases
10  US cities,
Adults/Adolescents
Spectrum of HIV
Disease  (ASD) Study
1992a to September
1999
1996–1998: 4.7/100 PYd Patient inclusion criteria: no CD4 criteria;
Disease deﬁnition: not clearly stated, likely
considers all episodes after cohort enrollment
Schwarcz, 2013, AIDS San Francisco, US,
SFDHP
January  1993 to
December  2008
1993–1995: 9.5/100 PY;
1996–2000:  2.15/100 PY;
2001–2008:  0.84/100 PY
Patient inclusion criteria: no CD4 criteria;
Disease deﬁnition: considers only the ﬁrst
episode after cohort enrollment
Ledergerber, 1999, Journal
of  the American
Medical Association
7  centers in
Switzerland, Swiss
HIV  Cohort Study
September 1995 to
March  1999
Before ART use: 2.35/100 PY,
after  ART use: 0.22/100 PY
Patient inclusion criteria: no CD4 criteria,
patients who started ART between September
1995 and December 1997. Disease deﬁnition: only
ﬁrst episode considered after cohort enrollment
Mocroft, 2000, Lancet 51 centers in Europe,
Eurosida  cohort
December 1995 to
spring  1999a
Non-ART regimens: 2.3/100 PY;
ART  regimens: 0.5/100 PY
Patient inclusion criteria: CD4 < 500 cells/mm3;
Disease deﬁnition: considers the ﬁrst episode
after cohort enrollment
Wohl, 2003, Aids Patient
Care  and STDs
10  US cities, ASD
cohort
1996a to 2000a US born: 3.6/100 PY; Mexican
born:  2.7/100 PY; Central
American  born: 1.3/100 PY
Patient inclusion criteria: no CD4 criteria;
included US born Latinos, Mexican born Latinos
and Central American Latinos. Disease
deﬁnition: not clear stated, apparently included
all episodes presented in the study period
Low/middle-income settings
Badri,  2005, The Southern
African  Journal of HIV
Medicine
Cape  Town, South
Africa,  Cape Town
AIDS  Cohort (CTAC)
1992a to December
2000
1.19/100 PY Patient inclusion criteria: no CD4 criteria;
Disease deﬁnition: not clearly stated, likely
considers all episodes after cohort enrollment
Hung, 2000, Journal of
Acquired  Immune
Deﬁciency Syndromes
Taiwan,  National
Taiwan  University
Hospital
June  1994 to June
1999
1995:  70.5/100 PY; 1999: 9.2/100
PY
Patient  inclusion criteria: no CD4 criteria;
Disease deﬁnition: considers only the ﬁrst
episode after cohort enrollment
Holmes, 2006, Journal of
Acquired  Immune
Deﬁciency Syndromes
Cape  Town, South
Africa,  University of
Cape  Town cohort
1994a to 2000a CD4 < 50: 8.1/100 PY; CD4
51–200: 0.6/100 PY; CD4
201–350:  0.3/100 PY; CD4 > 350: 0
Patient  inclusion criteria: patients with at least
two CD4 cell counts; Disease deﬁnition: WHO
stage III and IV, considers only ﬁrst episode
considered after cohort enrollment. Results were
stratiﬁed by CD4
Podlasin, 2006, Infection 10 centers in Poland 2000a to 2002a 2000: 0.89/100 PY; 2001:
0.82/100  PY; 2002: 0.5/100 PY
Patient inclusion criteria: none; Disease
deﬁnition: not clearly stated, likely considers all
episodes after cohort enrollment
Rojanawiwat, 2011,
International  Health
Lampang,  Thailand,
Governmental
Referral  Hospitale
July 2000 to October
2004
Prior  to ART: 4.7/100 PY; After
ART  use: 0.3/100 PY
Patient inclusion criteria: none; Disease
deﬁnition: not clearly stated, likely considers the
ﬁrst episode after cohort enrollment
ADI: AIDS deﬁning illness; ART: highly active antiretroviral therapy; MSM: men who have sex with men; PCP: Pneumocytis carinii pneumonia.
a Month not speciﬁed.
b Zidovudine, didanosine or both.
c PCP prophylaxis was prescribed for patients with CD4 count less than 200 cells/mm3 or considered at risk by their clinicians (even if CD4 > 200 cells/mm3).
d Results for other years shown in ﬁgure format only, thus not reported here.
e In 2002 the government introduced the co-formulation stavudine, lamivudine and nevirapine (on a pilot basis). The use of this medication gradually increased especially after 2004.
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Table 3 – Incidence rates for cerebral toxoplasmosis among HIV-infected individuals from high and low/middle-income settings.
First author, year, journal Setting and cohort
(when  applicable)
Time period evaluated Incidence rate estimate Notes
High-income settings
Bacellar,  1994, Journal of
Infectious  Diseases
Baltimore,
Pittsburgh,  Chicago
and  Los Angeles, US,
MACS  cohort
1985a to 1993a No antiretroviral nor PCP
prophylaxis:  6.9/100 PY; Only
antiretroviral:  6.0/100 PY;
Antiretroviral  and PCP
prophylaxis:  14.8/100 PY
Patient inclusion criteria: CD4 < 100 cells/mm3,
MSM only; Disease deﬁnition: considers only the
ﬁrst episode after cohort enrollment. Results
stratiﬁed by use of antiretroviralb and/or PCP
prophylaxis
Yazdanpanah, 2001,
International  Journal of
Epidemiology
France,  Tourcoing
and  Aquitaine
cohorts
January 1987 to
December  1995
>500  cells/mm3: 0.1/100 PY;
301–500 cells/mm3: 0.6/100 PY;
201–300 cells/mm3: 1.1/100 PY;
101–200 cells/mm3: 2.0/100 PY;
51–100 cells/mm3: 3.9/100 PY;
>50 cells/mm3: 12.6/100 PY
Patient  exclusion criteria:patients in use of
antiretroviral therapy other than zidovudine
monotheray and prophylaxis; patients with less
than 3 CD4 counts; patients with prior NTX
diagnosis or with NTX diagnosis in the ﬁrst
cohort visit and those in use of NTX prophylaxis.
Disease deﬁnition: only the ﬁrst case after cohort
enrollment. Results stratiﬁed by CD4 counts
Moore, 1996, Annals of
Internal  Medicine
Baltimore,  US, Johns
Hopkins  Clinical
Cohort
July 1989 to April
1995
2.3/100  PY Patient inclusion criteria: CD4 < 300 cells/mm3;
Disease deﬁnition: considers only the ﬁrst
episode after cohort enrollment
San-Andres, 2003, Clinical
Infectious Diseases
Madrid,  Spain,
University Hospital
January 1989 to
1997a
1989–1991: 2.1/100 PY, 1992:
2.9/100  PY, 1993: 2.4/100 PY,
1994:  0.8/100 PY, 1995: 1.1/100
PY,  1996: 1.0/100 PY, 1997:
1.8/100  PY
Patient inclusion criteria: CD4 < 500 cells/mm3 or
previous diagnosis of AIDS; Disease deﬁnition:
not clearly stated, likely considers all episodes
after cohort enrollment
Sacktor, 2001, Neurology Baltimore,
Pittsburgh, Chicago
and  Los Angeles, US,
MACS  cohort
January 1990 to
December  1998
1990–1992:  0.54/100 PY,
1993–1995:  0.38/100 PY,
1996–1998:  0.22/100 PY
Patient inclusion criteria: no CD4 criteria, MSM
only; Disease deﬁnition: not clearly stated, likely
considers all episodes after cohort enrollment
Brodt, 1997, AIDS Frankfurt, Germany,
Frankfurt  AIDS
Cohort
January 1992 to
March  1997
1992:  10.6/100 PY, 1993: 6.1/100
PY,  1994: 3.9/100 PY, 1995:
4.0/100  PY, 1996: 2.6/100 PY
Patient inclusion criteria: CD4 < 200 cells/mm3,
MSM only; Disease deﬁnition: not clearly stated,
likely considers all episodes after cohort
enrollment
Ledergerber, 1999, Journal
of  the American
Medical Association
7  centers in
Switzerland, Swiss
HIV  Cohort Study
September 1995 to
March  1999
Before  ART use: 1.45/100 PY,
after ART use: 0.18/100 PY
Patient inclusion criteria: no CD4 criteria,
patients who started ART between September
1995 and December 1997. Disease deﬁnition:
considers only the ﬁrst episode after cohort
enrollment
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Table 3 (Continued )
First author, year, journal Setting and cohort
(when  applicable)
Time period evaluated Incidence rate estimate Notes
Wohl, 2003, Aids Patient
Care  and STDs
10  US cities, ASD
cohort
1996a to 2000a US born: 0; Mexican born:
0.5/100  PY; Central American
born:  0.7/100 PY
Patient inclusion criteria: no CD4 criteria;
included US born Latinos, Mexican born Latinos
and Central American Latinos. Disease
deﬁnition: not clear stated, likely considers all
episodes presented in the study period
Garvey, 2011, European
Journal  of Neurology
10  UK HIV centers,
CHIC  (UK
Collaborative HIV
Cohort)
January 1996 to
December  2007
Total:  0.12/100 PY; 1996–1997:
0.32/100  PY, 1998–1999: 0.11/100
PY, 2000–2001: 0.15/100 PY,
2002–2003:  0.11/100 PY,
2004–2005:  0.09/100 PY,
2006–2007:  0.04/100 PY
Patient inclusion criteria: none; Disease
deﬁnition: considers only the ﬁrst episode after
cohort enrollment
Riveiro-Barciela, 2013,
HIV  medicine
Barcelona,  Spain January 2000 to
December  2010
2000  to June 2005: 0.32/100 PY;
July  2005–2010: 0.11/100 PY
Patient inclusion criteria: none; Disease
deﬁnition: not clearly stated, likely considers all
episodes after cohort enrollment
Low/middle-income settings
Badri,  2005, The Southern
African  Journal of HIV
Medicine
Cape  Town, South
Africa,  Cape Town
AIDS  Cohort (CTAC)
1992a to December
2000
0.15/100 PY Patient inclusion criteria: no CD4 criteria;
Disease deﬁnition: not clearly stated, likely
considers all episodes after cohort enrollment
Holmes, 2006, Journal of
Acquired  Immune
Deﬁciency Syndromes
Cape  Town, South
Africa,  University of
Cape  Town cohort
1994a to 2000a CD4 < 50: 1.2/100 PY; CD4
51–200: 0; CD4 201–350: 0;
CD4  > 350: 0
Patient  inclusion criteria: patients with at least
two CD4 cell counts; Disease deﬁnition: WHO
stage III and IV; considers only ﬁrst episode after
cohort enrollment. Results were stratiﬁed by CD4
Rojanawiwat, 2011,
International  Health
Lampang, Thailand,
Governmental
Referral  Hospitalc
July 2000 to October
2004
Before  ART use: 1.2/100 PY,
After  ART use: 1.0/100 PY
Patient inclusion criteria: none; Disease
deﬁnition: not clearly stated, likely considers all
episodes after cohort enrollment
ART: highly active antiretroviral therapy; MSM: men who have sex with men; NTX: Cerebral toxoplasmosis; PCP: Pneumocytis carinii pneumonia.
a Month not speciﬁed.
b Zidovudine, didanosine or both.
c In 2002 the government introduced the co-formulation stavudine, lamivudine and nevirapine (on a pilot basis). The use of this medication gradually increased especially after 2004.
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Table 4 – Incidence rate of Mycobacterium avium complex among HIV-infected individuals from high and low/middle-income settings.
First author, year, journal Setting and cohort
(when  applicable)
Time  period evaluated Incidence rate estimate Notes
High-income settings
Bacellar,  1994, Journal of
Infectious  Diseases
Baltimore,
Pittsburgh,  Chicago
and  Los Angeles, US,
MACS  cohort
1985a to 1993a No antiretroviral nor PCP prophylaxis:
6.9/100  PY; Only antiretroviral: 6.0/100 PY;
Antiretroviral and PCP prophylaxis:
14.8/100  PY
Patient  inclusion criteria: CD4 < 100 cells/mm3, MSM
only; Disease deﬁnition: CDC 1993; considers only
the ﬁrst episode of each ADI after cohort
enrollment. Results stratiﬁed by use of
antiretroviralb and/or PCP prophylaxis
Chaisson, 1992, American
review  of respiratory
disease
Multicenter
observational cohort
in  US
April  1987 to 1990c 8.6/100 PY Patient inclusion criteria: patients with AIDS
diagnoses deﬁned by PCP, an opportunistic disease
other than PCP and CD4 < 250 cells/mm3, or AIDS
related complex and CD4 < 250 cells/mm3; Disease
deﬁnition: not clearly stated, likely considers only
the ﬁrst episodes after cohort enrollment
Yazdanpanah, 2001,
International  Journal of
Epidemiology
France,  Tourcoing
and  Aquitaine
cohorts
January  1987 to
December  1995
>500 cells/mm3: 0.0/100 PY; 301–500
cells/mm3: 0.2/100 PY; 201–300 cells/mm3:
0.3/100 PY; 101–200 cells/mm3: 1.0/100 PY;
51–100 cells/mm3: 1.9/100 PY; >50
cells/mm3: 9.5/100 PY
Patient exclusion criteria: patients in use of
antiretroviral therapy other than zidovudine
monotheray and prophylaxis; patients with less
than 3 CD4 counts; excluded patients with prior
MAC diagnosis or with MAC diagnosis in the ﬁrst
cohort visit and those in use of MAC prophylaxis.
Disease deﬁnition: considers only the ﬁrst case after
cohort enrollment. Results stratiﬁed by CD4 counts
Mocroft, 1999, Journal of
Acquired  Immune
Deﬁciency Syndromes
London,  England,
Royal  Free Center for
HIV  Medicine
1987c to 1998c Before 1992: 1.1/100 PY, 1992–1993: 3.8/100
PY, 1994: 4.1/100 PY, 1995: 4.1/100 PY, 1996:
2.7/100 PY, 1997: 1.0/100 PY
Patient inclusion criteria: no CD4 criteria; Disease
deﬁnition: considers only the ﬁrst episode after
cohort enrollment
Moore, 1996, Annals of
Internal  Medicine
Baltimore, US, Johns
Hopkins  Clinical
Cohort
July  1989 to April
1995
7.4/100 PY Patient inclusion criteria: CD4 < 300 cells/mm3;
Disease deﬁnition: considers only the ﬁrst episode
after cohort enrollment
San-Andres, 2003, Clinical
Infectious Diseases
Madrid,  Spain,
University Hospital
January 1989 to
1997c
1989–1991: 1.5/100 PY, 1992: 2.9/100 PY,
1993: 1.5/100 PY, 1994: 1.1/100 PY, 1995:
1.9/100 PY, 1996: 2.5/100 PY, 1997: 0.6/100
PY
Patient inclusion criteria: CD4 < 500 cells/mm3 or
previous diagnosis AIDS; Disease deﬁnition: not
clearly stated, likely considers all episodes after
cohort enrollment
Charurat, 2004, Journal of
Women’s  Health
4  states in US and
Puerto  Rico, WITS
Cohort
December  1989 to
June  2002
Before February 1994: 0.32/100 PY; March
1994 to July 1996: 0.23/100 PY; After
August  1996: 0.12/100 PY
Patient inclusion criteria: no CD4 criteria, women
only, without previous diagnosis of AIDS; Disease
deﬁnition: considers only the ﬁrst episode after
cohort enrollmentd
Rossi, 2001, Swiss
Medical  Weekly
7  centers in
Switzerland, Swiss
HIV  Cohort Study
January 1990 to
December  1999
Overall: 5.8/100 PY, 1990–1996: 8.8/100 PY,
1997–1999: 1.4/100 PY
Patient  inclusion criteria: CD4 < 50 cells/mm3;
Disease deﬁnition: considers only the ﬁrst episode
after cohort enrollment
Brodt, 1997, AIDS Frankfurt, Germany,
Frankfurt  AIDS
Cohort
January  1992 to
March  1997
1992: 4.5/100 PY; 1993: 6.1/100 PY; 1994:
6.6/100 PY; 1995: 5.4/100 PY; 1996: 2.8/100
PY;
Patient inclusion criteria: CD4 < 200 cells/mm3, MSM
only; Disease deﬁnition: not clearly stated, likely
considers all episodes after cohort enrollment
Kaplan, 2000, Clinical
Infectious  Diseases
10  US cities,
Adults/Adolescents
Spectrum of HIV
Disease  (ASD) Study
1992c to September
1999
1996–1998: 3.4/100 PYe Patient inclusion criteria: no CD4 criteria; Disease
deﬁnition: not clearly stated, likely considers all
episodes after cohort enrollment
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Table 4 (Continued )
First author, year, journal Setting  and cohort
(when  applicable)
Time  period evaluated Incidence  rate estimate Notes
Schwarcz, 2013, AIDS San  Francisco, US,
SFDHP
January  1993 to
December  2008
1993–1995: 8.52/100 PY; 1996–2000:
1.34/100  PY; 2001–2008: 0.32/100 PY
Patient inclusion criteria: no CD4 criteria; Disease
deﬁnition: considers only the ﬁrst episode after
cohort enrollment
Kirk, 2000, American
Journal  of Respiratory
and  Critical Care
Medicine
17  European
countries, EuroSIDA
Cohort
May  1994 to
February 1999
1.38/100 PY Patient inclusion criteria: no CD4 criteria; Disease
deﬁnition: considers only the ﬁrst episode after
cohort enrollment
Mocroft, 2000, Lancet 51 centers in Europe,
Eurosida  cohort
May 1994 to spring
1999c
Non-ART regimens: 2.3/100 PY; ART
regimens: 0.5/100 PY
Patient  inclusion criteria: CD4 < 500 cells/mm3;
Disease deﬁnition: considers only the ﬁrst episode
after cohort enrollment
Baril, 2000, AIDS Paris, France,
Pitié-Salpêtrière
Hospital
January  1995 to
December  1997
January 1996 to June 1996: 13.4/100 PY;
July 1996 to December 1997: 2.6/100 PY
Patient inclusion criteria: no CD4 criteria; Disease
deﬁnition: considers the ﬁrst episode after cohort
enrollment
Ledergerber, 1999, Journal
of  the American
Medical Association
7  centers in
Switzerland, Swiss
HIV  Cohort Study
September 1995 to
March  1999
Before ART use: 1.79/100 PY; after ART
use: 0.76/100 PY
Patient  inclusion criteria: no CD4 criteria, patients
who started ART between September 1995 and
December 1997. Disease deﬁnition: considers only
the ﬁrst episode after cohort enrollmentd
Wohl, 2003, Aids Patient
Care  and STDs
10  US cities, ASD
cohort
1996c to 2000c US born: 1.8/100 PY; Mexican born: 1.1/100
PY; Central American born: 0.4/100 PY
Patient inclusion criteria: no CD4 criteria; included
US born Latinos, Mexican born Latinos and Central
American Latinos. Disease deﬁnition: not clear
stated, apparently included all OI presented in the
study period
Low/middle-income settings
Badri,  2005, The Southern
African  Journal of HIV
Medicine
Cape  Town, South
Africa,  Cape Town
AIDS  Cohort (CTAC)
1992c to December
2000
0.40/100 PY Patient inclusion criteria: no CD4 criteria; Disease
deﬁnition: disseminated atypical mycobacteria;
likely considers all episodes after cohort enrollment
Bonard, 2004, AIDS Ivory Coast, Cotrame
ANRS  1203
1992c to October
2002
1.85/100 PY Patient inclusion criteria: no CD4 criteria; Disease
deﬁnition: considers only the ﬁrst episode after
cohort enrollmentd
Gadelha, 2002, The
Brazilian  Journal of
Infectious  Diseases
Rio  de Janeiro, Brazil,
IPEC cohort
September  1997 to
December  1999
0 Patient inclusion criteria: CD4 < 100 cells/mm3;
Excluded patients under MAC treatment or
prophylaxis. Disease deﬁnition: considers only the
ﬁrst episode presented in the study period
ART: highly active antiretroviral therapy; MAC: Mycbacterium avium complex; MSM: men who have sex with men; PCP: Pneumocystis carinii pneumonia.
a Time inferred from information contained in the text.
b Zidovudine, didanosine or both.
c Month not speciﬁed.
d Classify as Mycobacterium non tuberculosis.
e Results for other years shown in ﬁgure format only, thus not reported here.
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Table 4, including results from England, France, Spain, Switzer-
land,  and Germany.
In  LMIS, two studies from Africa and one from Brazil report
incidence rates of MAC.  The South African study, with no
CD4+ cell count restriction of the study population reported
an  incidence rate of 0.4/100 PY for the period of 1992–2000.22
Another study, from Ivory Coast including all HIV-infected
found an incidence rate of 1.85/100 PY for the period of
1992–2002.24 The study from Brazil, conducted from 1997 to
1999  among patients with CD4+ cell counts less than 100
cells/mm3 reported no cases of disseminated MAC.25
Discussion
Through a systematic review of the literature, we have shown
that  the incidence of opportunistic illnesses decreased over
the  30 years of the HIV epidemic, markedly after ART avail-
ability.  The signiﬁcant reduction in the incidence rates was
demonstrated for opportunistic illnesses overall and also for
speciﬁc opportunistic infections, namely, PCP, NXT and MAC.
In  addition, the decreasing trends were  shown for both HIS and
LMIS  where ART was  made available. This result is extremely
positive  as it shows that opportunistic illnesses can be con-
trolled  while also pointing to the persistent challenge of a
timely  diagnosis of HIV infection. Indeed, in order to control
opportunistic illnesses HIV infection status must be identi-
ﬁed  and earlier linkage to care needs to be facilitated. That is,
a  higher uptake of HIV testing with direct linkage to care of
those  found to be HIV-infected is urgently needed.
We  found that the magnitude of the incidence rates and
of  the reduction of these rates as a function of ART var-
ied  between studies. Indeed, it is well known that there are
geographical differences in the incidence of opportunistic
illnesses.26 Other reasons for the differences in the baseline
rates  might include different study populations, including dif-
ferent sociodemographic subgroups evaluated in a speciﬁc
study,  for example, the MACS  cohort that focuses on men
who  have sex men,27 as well as different inclusion criteria.
Some  studies included all HIV-infected individuals while oth-
ers  restricted the study population to individuals with speciﬁc
CD4+ cell counts, for example, including only those with CD4+
cell count less than 100 cells/mm3.15 Moreover, different study
deﬁnitions  with respect to the diseases chosen to be included
in  any given study might have further contributed to the dis-
parate  results.
Out  of the 37 studies included in the present review, almost
70%  were  from HIS. Of the 12 studies from LMIS, four stud-
ies  were  from Brazil.13–15,25 These studies reported incidence
rates for opportunistic illnesses for the entire study period
included  in the respective study and not annual rates that
could  allow us to evaluate the temporal trends in incidence.
Also,  only one study from Brazil reported separately on the
incidence  rate of MAC.  However, this study reported no cases
of  the disease, a ﬁnding that could have been due to the small
sample  size and/or short follow-up. For other important dis-
eases  that deﬁne the AIDS epidemic, namely, PCP, and NXT,
no  studies from Brazil were found. Furthermore, all are single
center  cohort studies, two from São Paulo (Hospital das Clíni-
cas,  Faculdade de Medicina da Universidade de São Paulo) and 1 4;1  8(2):196–210
two from Rio de Janeiro (Instituto de Pesquisa Clínica Evandro
Chagas,  Fundac¸ão  Oswaldo Cruz). We believe that the descrip-
tion  of the trends in incidence rates of opportunistic illnesses
is  of paramount value to health care providers to guide clini-
cal  decision-making and policy makers to deﬁne priorities for
care and prevention of opportunistic infections.
Strengths and limitations to the present study are worth
mentioning. Through a systematic review conducted in four
databases  we found the epidemiological studies that reported
on  the incidence rate of opportunistic illnesses. We restricted
the  review to those studies reporting on rates (and not overall
numbers  or frequencies) since this epidemiological parame-
ter  is adjusted for population size and time under risk thus
allowing  for comparisons between studies. Though not a limi-
tation  of our study design and approach, the scarcity of studies
from  LMIS implies that we cannot adequately describe the
patterns  of incidence in these settings. In addition, the few
studies  found should also not be understood as representative
of  entire countries as they report from one center only. Finally,
the  different study methodologies such as inclusion criteria
and  diseases included, for example, limited the comparisons.
In  conclusion, the incidence rate of opportunistic illnesses
has  decreased over time mainly due to the availability of
highly  effective, safe and well tolerated ART. However, a pub-
lic  health challenge remains for future years. Public health
policies  focusing on earlier HIV diagnosis and linkage to care,
adherence  and retention programs, and surveillance of HIV
multidrug  resistance in populations should be developed and
implemented  with the goal of improving the quality of life
and  reducing morbidity and mortality among HIV-infected
individuals. To better understand the nuances of the epidemi-
ology  of opportunistic illnesses in LMIS, multicenter cohort
studies  should be encouraged. Finally, it is clear that studies
from  Brazil are urgently needed to assess the current burden
of  opportunistic illnesses in order to support the planning of
HIV/AIDS  health care services organization.
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